Goldman Sachs Group Inc Immunic, Inc. Call Options Transaction History
Goldman Sachs Group Inc
- $605 Billion
- Q3 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding IMUX
# of Institutions
70Shares Held
56.3MCall Options Held
100Put Options Held
350K-
Bvf Inc San Francisco, CA8.9MShares$8.55 Million0.47% of portfolio
-
Avidity Partners Management LP Dallas, TX8.27MShares$7.94 Million0.84% of portfolio
-
Soleus Capital Management, L.P. Greenwich, CT7.29MShares$7 Million1.02% of portfolio
-
Adage Capital Partners Gp, L.L.C. Boston, MA5.59MShares$5.37 Million0.02% of portfolio
-
Janus Henderson Group PLC London, X05.1MShares$4.9 Million0.0% of portfolio
About IMMUNIC, INC.
- Ticker IMUX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 30,565,000
- Market Cap $29.3M
- Description
- Immunic, Inc., a clinical-stage biopharmaceutical company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases. Its lead development program is IMU-838, which is in Phase 2 clinical for treatment of relapsing-remitting multiple sclerosis, inflammatory bowel disease, and oth...